Leslie Khawli

Professor Of Clinical Pathology

Director of the Pathology Graduate Program

Image of Leslie Khawli
Is this your profile? Click to edit

Publications

  • Enhancing brain entry and therapeutic activity of chimeric antigen receptor T cells with intra-arterial NEO100 in a mouse model of CNS lymphoma J Neurosurg. 2023 Dec 29; 1-9. . View in PubMed
  • Brain Disposition of Antibody-Based Therapeutics: Dogma, Approaches and Perspectives Int J Mol Sci. 2021 Jun 16; 22(12). . View in PubMed
  • Spatio-temporal biodistribution of 89Zr-oxine labeled huLym-1-A-BB3z-CAR T-cells by PET imaging in a preclinical tumor model Sci Rep. 2021 07 23; 11(1):15077. . View in PubMed
  • Advances in Immuno-PET for the Detection of Cancer and Assessment of Response to Therapy Curr Med Chem. 2021; 28(4):647-672. . View in PubMed
  • Principles of N-Linked Glycosylation Variations of IgG-Based Therapeutics: Pharmacokinetic and Functional Considerations Antibodies (Basel). 2020 Jun 10; 9(2). . View in PubMed
  • A Humanized Lym-1 CAR with Novel DAP10/DAP12 Signaling Domains Demonstrates Reduced Tonic Signaling and Increased Antitumor Activity in B-Cell Lymphoma Models Clin Cancer Res. 2020 07 15; 26(14):3694-3706. . View in PubMed
  • Biodistribution and efficacy of an anti-TENB2 antibody-drug conjugate in a patient-derived model of prostate cancer Oncotarget. 2019 Oct 22; 10(58):6234-6244. . View in PubMed
  • Lym-1 Chimeric Antigen Receptor T Cells Exhibit Potent Anti-Tumor Effects against B-Cell Lymphoma Int J Mol Sci. 2017 Dec 20; 18(12). . View in PubMed
  • Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor models Cancer Immunol Immunother. 2016 May; 65(5):511-23. . View in PubMed
  • Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development MAbs. 2016; 8(2):229-45. . View in PubMed
  • Recent Advances in Assessing Immunogenicity of Therapeutic Proteins: Impact on Biotherapeutic Development J Immunol Res. 2016; 2016:8141269. . View in PubMed
  • Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins J Immunol Res. 2016; 2016:2342187. . View in PubMed
  • Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics J Biol Chem. 2015 Dec 11; 290(50):29732-41. . View in PubMed
  • A novel in vitro method to model the fate of subcutaneously administered biopharmaceuticals and associated formulation components J Control Release. 2015 Sep 28; 214:94-102. . View in PubMed
  • Comparative physiology of mice and rats: radiometric measurement of vascular parameters in rodent tissues Mol Pharm. 2014 May 05; 11(5):1591-8. . View in PubMed
  • Quantitative cumulative biodistribution of antibodies in mice: effect of modulating binding affinity to the neonatal Fc receptor MAbs. 2014 May-Jun; 6(3):689-96. . View in PubMed
  • Dose dependent pharmacokinetics, tissue distribution, and anti-tumor efficacy of a humanized monoclonal antibody against DLL4 in mice MAbs. 2014; 6(6):1631-7. . View in PubMed
  • Enhanced tumor retention of a radiohalogen label for site-specific modification of antibodies J Med Chem. 2013 Dec 12; 56(23):9418-26. . View in PubMed
  • Cytoreductive chemotherapy improves the biodistribution of antibodies directed against tumor necrosis in murine solid tumor models Mol Cancer Ther. 2013 Dec; 12(12):2827-36. . View in PubMed
  • Drug delivery across the blood-brain barrier Mol Pharm. 2013 May 06; 10(5):1471-2. . View in PubMed
  • Vascular physiology and protein disposition in a preclinical model of neurodegeneration Mol Pharm. 2013 May 06; 10(5):1514-21. . View in PubMed
  • Generation of tumor-targeted antibody-CpG conjugates J Immunol Methods. 2013 Mar 29; 389(1-2):45-51. . View in PubMed
  • Characterization of therapeutic monoclonal antibodies reveals differences between in vitro and in vivo time-course studies Pharm Res. 2013 Jan; 30(1):167-78. . View in PubMed
  • An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2 Br J Pharmacol. 2013 Jan; 168(2):445-57. . View in PubMed
  • Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics AAPS J. 2012 Sep; 14(3):554-8. . View in PubMed
  • Differential effects of predosing on tumor and tissue uptake of an 111In-labeled anti-TENB2 antibody-drug conjugate J Nucl Med. 2012 Sep; 53(9):1454-61. . View in PubMed
  • Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations AAPS J. 2012 Sep; 14(3):612-8. . View in PubMed
  • Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice Br J Pharmacol. 2012 May; 166(1):368-77. . View in PubMed
  • Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges World J Biol Chem. 2012 Apr 26; 3(4):73-92. . View in PubMed
  • Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration MAbs. 2012 Mar-Apr; 4(2):243-55. . View in PubMed
  • Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model Mol Cancer Ther. 2012 Mar; 11(3):752-62. . View in PubMed
  • Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates Nat Biotechnol. 2012 Jan 22; 30(2):184-9. . View in PubMed
  • Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats Bioconjug Chem. 2011 Oct 19; 22(10):1994-2004. . View in PubMed
  • Antibody delivery of drugs and radionuclides: factors influencing clinical pharmacology Ther Deliv. 2011 Jun; 2(6):769-91. . View in PubMed
  • Effects of anti-VEGF on predicted antibody biodistribution: roles of vascular volume, interstitial volume, and blood flow PLoS One. 2011 Mar 15; 6(3):e17874. . View in PubMed
  • Effects of charge on antibody tissue distribution and pharmacokinetics Bioconjug Chem. 2010 Dec 15; 21(12):2153-63. . View in PubMed
  • Effect of immune complex formation on the distribution of a novel antibody to the ovarian tumor antigen CA125 Drug Metab Dispos. 2010 Dec; 38(12):2309-19. . View in PubMed
  • Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats MAbs. 2010 Nov-Dec; 2(6):613-24. . View in PubMed
  • Development and evaluation of a novel method for preclinical measurement of tissue vascular volume Mol Pharm. 2010 Oct 04; 7(5):1848-57. . View in PubMed
  • Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models J Immunother. 2008 Apr; 31(3):235-45. . View in PubMed
  • Construction and preclinical characterization of Fc-mGITRL for the immunotherapy of cancer Clin Cancer Res. 2008 Jan 15; 14(2):579-88. . View in PubMed
  • Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors Handb Exp Pharmacol. 2008; (181):291-328. . View in PubMed
  • Lym-1-induced apoptosis of non-Hodgkin’s lymphomas produces regression of transplanted tumors Cancer Biother Radiopharm. 2007 Jun; 22(3):342-56. . View in PubMed
  • RA8, a human anti-CD25 antibody against human Treg cells Hybridoma (Larchmt). 2007 Jun; 26(3):119-30. . View in PubMed
  • Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors Clin Cancer Res. 2007 May 01; 13(9):2758-67. . View in PubMed
  • Soluble Fc fusion proteins for biomedical research Methods Mol Biol. 2007; 378:33-52. . View in PubMed
  • B71/NHS76: a new costimulator fusion protein for the immunotherapy of solid tumors. J Immunother. 2006 Jul-Aug; 29(4):425-35. . View in PubMed
  • H60/TNT-3 fusion protein activates NK cells in vitro and improves immunotherapeutic outcome in murine syngeneic tumor models J Immunother. 2006 May-Jun; 29(3):274-83. . View in PubMed
  • 131I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer Cancer Biother Radiopharm. 2006 Feb; 21(1):5-14. . View in PubMed
  • Combination B7-Fc fusion protein treatment and Treg cell depletion therapy Clin Cancer Res. 2005 Dec 01; 11(23):8492-502. . View in PubMed
  • Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin’s lymphomas Clin Cancer Res. 2005 Aug 15; 11(16):5971-80. . View in PubMed
  • NHS76/PEP2, a fully human vasopermeability-enhancing agent to increase the uptake and efficacy of cancer chemotherapy Clin Cancer Res. 2005 Apr 15; 11(8):3084-93. . View in PubMed
  • Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer J Clin Oncol. 2005 Mar 01; 23(7):1538-47. . View in PubMed
  • chTNT-3/hu IL-12 fusion protein for the immunotherapy of experimental solid tumors Hybrid Hybridomics. 2004 Feb; 23(1):1-10. . View in PubMed
  • Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion Cancer Res. 2003 Dec 01; 63(23):8384-92. . View in PubMed
  • Tumor targeting properties of indium-111 labeled genetically engineered Fab’ and F(ab’)2 constructs of chimeric tumor necrosis treatment (chTNT)-3 antibody Cancer Biother Radiopharm. 2003 Dec; 18(6):931-40. . View in PubMed
  • Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis Cancer Res. 2003 Aug 15; 63(16):5046-53. . View in PubMed
  • Chimeric TNT-3 antibody/murine interferon-gamma fusion protein for the immunotherapy of solid malignancies Hybrid Hybridomics. 2003 Aug; 22(4):197-207. . View in PubMed
  • LEC/chTNT-3 fusion protein for the immunotherapy of experimental solid tumors J Immunother. 2003 Jul-Aug; 26(4):320-31. . View in PubMed
  • Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity Blood. 2003 Jun 15; 101(12):4853-61. . View in PubMed
  • Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT) Cancer Biother Radiopharm. 2003 Jun; 18(3):339-53. . View in PubMed
  • Identification of a protein fragment of interleukin 2 responsible for vasopermeability J Natl Cancer Inst. 2003 May 21; 95(10):741-9. . View in PubMed
  • Neotrofin increases heme oxygenase-1 selectively in neurons Brain Res. 2003 Feb 07; 962(1-2):1-14. . View in PubMed
  • Comparison of recombinant derivatives of chimeric TNT-3 antibody for the radioimaging of solid tumors Hybrid Hybridomics. 2003 Feb; 22(1):1-9. . View in PubMed
  • Generation of human interferon gamma and tumor Necrosis factor alpha chimeric TNT-3 fusion proteins Hybrid Hybridomics. 2002 Dec; 21(6):421-32. . View in PubMed
  • Stable, genetically engineered F(ab’)(2) fragments of chimeric TNT-3 expressed in mammalian cells Hybrid Hybridomics. 2002 Feb; 21(1):11-8. . View in PubMed
  • Single amino acid substitution in the Fc region of chimeric TNT-3 antibody accelerates clearance and improves immunoscintigraphy of solid tumors J Nucl Med. 2000 Feb; 41(2):355-62. . View in PubMed
  • Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors Clin Cancer Res. 1999 Jan; 5(1):51-60. . View in PubMed
  • Improving monoclonal antibody pharmacokinetics via chemical modification Q J Nucl Med. 1998 Dec; 42(4):242-9. . View in PubMed
  • A new chemically modified chimeric TNT-3 monoclonal antibody directed against DNA for the radioimmunotherapy of solid tumors Cancer Biother Radiopharm. 1998 Aug; 13(4):255-68. . View in PubMed
  • Antitumor effects of nonconjugated murine Lym-2 and human-mouse chimeric CLL-1 monoclonal antibodies against various human lymphoma cell lines in vitro and in vivo Blood. 1997 Oct 15; 90(8):3160-6. . View in PubMed
  • Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties Blood. 1997 Jun 15; 89(12):4437-47. . View in PubMed
  • Exploration of novel strategies to enhance monoclonal antibodies targeting Q J Nucl Med. 1997 Mar; 41(1):25-35. . View in PubMed
  • A chimeric Lym-1/interleukin 2 fusion protein for increasing tumor vascular permeability and enhancing antibody uptake Cancer Res. 1996 Nov 01; 56(21):4998-5004. . View in PubMed
  • Improved tumor localization and radioimaging with chemically modified monoclonal antibodies Cancer Biother Radiopharm. 1996 Jun; 11(3):203-15. . View in PubMed
  • Identification of a monoclonal antibody, TV-1, directed against the basement membrane of tumor vessels, and its use to enhance the delivery of macromolecules to tumors after conjugation with interleukin 2 Cancer Res. 1995 Jun 15; 55(12):2673-80. . View in PubMed
  • A human-mouse chimeric Lym-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus system Hum Antibodies Hybridomas. 1995; 6(2):57-67. . View in PubMed
  • Effect of seven new vasoactive immunoconjugates on the enhancement of monoclonal antibody uptake in tumors Cancer. 1994 Feb 01; 73(3 Suppl):824-31. . View in PubMed
  • An improved method of direct labeling monoclonal antibodies with 99mTc Int J Rad Appl Instrum B. 1992 May; 19(4):445-54. . View in PubMed
  • N-(m-[125I]iodophenyl)maleimide: an agent for high yield radiolabeling of antibodies Int J Rad Appl Instrum B. 1992 Apr; 19(3):289-95. . View in PubMed
  • m-[125I]iodoaniline: a useful reagent for radiolabeling biotin Int J Rad Appl Instrum B. 1992 Apr; 19(3):297-301. . View in PubMed
  • Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate Cancer Res. 1991 May 15; 51(10):2694-8. . View in PubMed
  • Synthesis of 125I labeled N-succinimidyl p-iodobenzoate for use in radiolabeling antibodies Int J Rad Appl Instrum B. 1989; 16(7):727-33. . View in PubMed
  • Inhibition of herpesvirus and human DNA polymerases by alpha-halogenated phosphonoacetates Biochem Pharmacol. 1987 Oct 01; 36(19):3103-6. . View in PubMed